Insulet (PODD) AI Stock Analysis

• Market Cap: $21.46B
• Dividend Yield: N/A
• Average Volume (3M): 640.58K
• Price to Earnings (P/E): 92.8
• Beta (1Y): 1.11
• Revenue Growth: 25.99%
• EPS Growth: -40.46%
• Country: US
• Employees: 3,900
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Devices
• EPS (TTM): 1.17
• Shares Outstanding: 70,392,530
• 10 Day Avg. Volume: 787,177
• 30 Day Avg. Volume: 640,581
• PEG Ratio: 0.43
• Price to Book (P/B): 15.10
• Price to Sales (P/S): 8.83
• P/FCF Ratio: 59.90
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: 10.23
• Enterprise Value/Gross Profit: 14.53
• Enterprise Value/Ebitda: 53.77
• 1Y Price Target: $359.44
• Price Target Upside: 17.91% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 77 Outperform
• Price Target: $345.00 ▲(13.17% Upside)

Insulet's strong financial performance and positive earnings call are the most significant factors driving the stock score. The company's robust revenue growth and improved profitability, along with raised guidance, reflect a strong market position. However, the high valuation and mixed technical indicators slightly temper the overall score.

Positive Factors

International Sales

Insulet's reacceleration in International sales shaping up over the past several quarters is perhaps even more remarkable and remains an underappreciated part of the story.

Revenue Growth

Insulet beat revenue estimates across the board and confidently raised its guidance for FY25, with strength expected across all markets and populations.

Type 2 Market

Prescribers and patients are choosing Omnipod increasingly often, especially for Type 2, and Insulet is uniquely positioned amidst reimbursement trends favoring pay-as-you-go economics.

Negative Factors

Gross Margins

Lower SG&A expenses contributed to an EPS beat, despite lower gross margins.

Long-term Profitability

Investors are still concerned about longer-term adjusted OMs as management would not commit to continued expansion.

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation is a medical device company that specializes in the development and manufacturing of innovative insulin delivery systems, primarily for people with diabetes. The company is best known for its Omnipod Insulin Management System, which offers a tubeless, wearable insulin pump designed to improve the quality of life for individuals managing diabetes. Insulet operates in the healthcare sector, focusing on diabetes management and has expanded its product offerings to include advanced technology that integrates with continuous glucose monitoring systems.

How the Company Makes Money

Insulet generates revenue primarily through the sale of its Omnipod Insulin Management Systems and the related consumable products, such as insulin cartridges and infusion sets. The company has a subscription-based model for the consumables, which provides a recurring revenue stream as patients require ongoing supplies for their insulin delivery. Additionally, partnerships with healthcare providers and payers enhance its revenue model, as Insulet collaborates with insurance companies to ensure coverage for its products, thereby increasing accessibility for users. The company also invests in research and development to enhance its products, potentially leading to new revenue opportunities through innovation and improved technology integration with diabetes management solutions.

Insulet Financial Statement Overview

Summary

Insulet demonstrates strong financial performance with robust revenue growth and improved profitability. The balance sheet is solid with low leverage and high equity returns, while cash flow management is effective. However, there is room for improvement in maximizing margins and optimizing capital allocation.

Income Statement

Insulet has demonstrated strong revenue growth, particularly noticeable in its TTM (Trailing-Twelve-Months) performance with a significant increase over previous years. The gross profit margin is robust at approximately 76.5%, indicating efficient production management. The net profit margin and EBIT margin have also improved, reflecting enhanced operational efficiency and profitability. However, compared to some industry peers, there is scope for further improvement in EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a solid equity position with a debt-to-equity ratio of approximately 0.06, indicating low financial leverage and risk. Insulet's return on equity (ROE) is impressive at approximately 30.22%, showcasing strong shareholder returns. The equity ratio is about 37.8%, affirming a stable financial structure, although there is room to enhance asset utilization.

Cash Flow

Insulet's cash flow management is commendable with positive free cash flow and a healthy operating cash flow to net income ratio. The free cash flow growth is stable, contributing to financial flexibility. However, there is potential to optimize capital expenditures further to enhance free cash flow generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.20B	2.07B	1.70B	1.31B	1.10B	904.40M
Gross Profit	1.55B	1.45B	1.16B	805.60M	752.10M	582.30M
EBITDA	418.30M	423.70M	323.60M	109.50M	139.60M	110.30M
Net Income	402.20M	418.30M	206.30M	4.60M	16.80M	6.80M
Balance Sheet
Total Assets	3.52B	3.09B	2.59B	2.25B	2.05B	1.87B
Cash, Cash Equivalents and Short-Term Investments	1.28B	953.40M	704.20M	674.70M	791.60M	947.60M
Total Debt	1.70B	1.39B	1.42B	1.40B	1.25B	1.04B
Total Liabilities	2.19B	1.88B	1.86B	1.77B	1.49B	1.27B
Stockholders Equity	1.33B	1.21B	732.70M	476.40M	556.30M	603.60M
Cash Flow
Free Cash Flow	290.90M	305.40M	36.50M	-38.30M	-190.80M	-82.50M
Operating Cash Flow	406.50M	430.30M	145.70M	119.00M	-68.10M	84.00M
Investing Cash Flow	-137.90M	-146.20M	-119.40M	-191.10M	-82.70M	14.00M
Financing Cash Flow	263.80M	-28.10M	-13.60M	-40.30M	40.70M	605.50M

Insulet Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 304.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Positive. The current price of 304.84 is above the 20-day moving average (MA) of 289.64, above the 50-day MA of 299.66, and above the 200-day MA of 276.22, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 58.55 is Neutral, neither overbought nor oversold. The STOCH value of 61.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PODD.

Insulet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STE	80 Outperform	$23.92B	36.82	9.73%	0.94%	2.47%	63.68%
PODD	77 Outperform	$21.46B	92.77	19.18%	―	25.99%	-40.46%
SNN	76 Outperform	$15.76B	31.81	9.20%	2.09%	6.28%	61.96%
DXCM	75 Outperform	$30.53B	54.50	22.83%	―	9.30%	-14.95%
PHG	56 Neutral	$25.54B	―	-7.10%	3.32%	-0.76%	-55.03%
Sector *	51 Neutral	$7.35B	-0.20	-44.86%	2.33%	28.96%	-1.05%
TNDM	46 Neutral	$683.47M	―	-111.91%	―	25.84%	-47.67%

Insulet Corporate Events

Insulet Issues Redemption Notice for Convertible Notes

On June 6, 2025, Insulet Corporation amended its Credit Agreement to refinance $481.25 million in term loans, reducing the interest rate margin and maintaining similar terms to the previous loans. Additionally, Insulet issued a redemption notice on June 9, 2025, for its outstanding Convertible Senior Notes due 2026, with plans to redeem them by August 20, 2025, potentially impacting stock transactions as hedge positions are unwound.

The most recent analyst rating on (PODD) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Corporation Holds 2025 Annual Stockholders Meeting

Insulet Corporation held its 2025 Annual Meeting of Stockholders on May 22, 2025, where shareholders elected three Class III directors, approved executive compensation, and ratified the appointment of Grant Thornton LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. Additionally, the Insulet Corporation 2025 Stock Option and Incentive Plan was approved, indicating continued shareholder support for the company’s strategic initiatives and governance practices.

The most recent analyst rating on (PODD) stock is a Hold with a $185.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.